>
Switch to:

CRISPR Therapeutics AG PS Ratio

: 11.11 (As of Today)
View and export this data going back to 2016. Start your Free Trial

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CRISPR Therapeutics AG's share price is $124.52. CRISPR Therapeutics AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $11.21. Hence, CRISPR Therapeutics AG's PS Ratio for today is 11.11.

Good Sign:

CRISPR Therapeutics AG stock PS Ratio (=10.47) is close to 1-year low of 10.11

The historical rank and industry rank for CRISPR Therapeutics AG's PS Ratio or its related term are showing as below:

NAS:CRSP' s PS Ratio Range Over the Past 10 Years
Min: 7.58   Med: 65.1   Max: 18170.91
Current: 11.09

7.58
18170.91

During the past 7 years, CRISPR Therapeutics AG's highest PS Ratio was 18170.91. The lowest was 7.58. And the median was 65.10.

NAS:CRSP's PS Ratio is ranked higher than
64% of the 993 Companies
in the Biotechnology industry.

( Industry Median: 20.82 vs. NAS:CRSP: 11.09 )

CRISPR Therapeutics AG's Revenue per Sharefor the three months ended in Jun. 2021 was $11.20. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 was $11.21.

Warning Sign:

CRISPR Therapeutics AG revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of CRISPR Therapeutics AG was 126.00% per year. During the past 3 years, the average Revenue per Share Growth Rate was -77.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 19.80% per year.

During the past 7 years, CRISPR Therapeutics AG's highest 3-Year average Revenue per Share Growth Rate was 129.50% per year. The lowest was -77.90% per year. And the median was 101.00% per year.

Back to Basics: PS Ratio


CRISPR Therapeutics AG PS Ratio Historical Data

The historical data trend for CRISPR Therapeutics AG's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
PS Ratio
Premium Member Only Premium Member Only 48.12 22.95 439.54 11.97 13,919.09

CRISPR Therapeutics AG Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PS Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.81 65.14 13,919.09 8,123.33 14.44

Competitive Comparison

For the Biotechnology industry, CRISPR Therapeutics AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

CRISPR Therapeutics AG PS Ratio Distribution

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's PS Ratio distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's PS Ratio falls into.



CRISPR Therapeutics AG PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

CRISPR Therapeutics AG's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=124.52/11.21
=11.11

CRISPR Therapeutics AG's Share Price of today is $124.52.
CRISPR Therapeutics AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.21.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


CRISPR Therapeutics AG  (NAS:CRSP) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


CRISPR Therapeutics AG PS Ratio Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CRISPR Therapeutics AG Business Description

CRISPR Therapeutics AG logo
Industry
Healthcare » Biotechnology NAICS : 0 SIC : 0
Traded in Other Exchanges
Address
Baarerstrasse 14, Zug, CHE, 6300
CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.
Executives
Novak Rodger director, officer: President C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139
Tomsicek Michael John officer: Chief Financial Officer 28 OVERLOOK DRIVE BEDFORD MA 01730
Klein Lawrence Otto officer: CBO & COO C/O CRISPR THERAPEUTICS AG 610 MAIN STREET 7TH FLOOR CAMBRIDGE MA 02139
Ho Tony W officer: Executive VP, Head of R&D CRISPR THERAPEUTICS AG 610 MAIN STREET CAMBRIDGE MA 02139
Kasinger James R. officer: General Counsel and Secretary C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139
Kulkarni Samarth director, officer: Chief Executive Officer C/O CRISPR THERAPEUTICS AG 200 SIDNEY STREET CAMBRIDGE MA 02139
Bolzon Bradley J Phd director ONE SANSOME STREET SUITE 3630 SAN FRANCISCO CA 94104
Behbahani Ali director 5425 WISCONSIN AVE CHEVY CHASE MD 20815
High Katherine A director 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Treco Douglas A director 87 CAMBRIDGEPARK DRIVE C/O RA PHARMACEUTICALS, INC. CAMBRIDGE MA 02140
George Simeon director 161 WASHINGTON STREET SUITE 500 CONSHOHOCKEN PA 19428
Greene John director 51 LIME STREET LONDON X0 EC3M 7DQ
Cagnoni Pablo J director ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080
Vertex Pharmaceuticals (europe) Ltd 10 percent owner 2 KINGDOM STREET, 9TH FLOOR LONDON X0 W2 6BD
Vertex Pharmaceuticals Inc / Ma 10 percent owner 50 NORTHERN AVENUE BOSTON MA 02210

CRISPR Therapeutics AG Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)